PLK1 and neoplasm: Rigosertib, an inhibitor of polo-like kinase 1 (PLK1), was identified as a promising drug candidate for the treatment of RDEB-SCC, and was shown to induce G2-M cell cycle arrest and apoptosis in RDEB-SCC cells, as well as inhibiting tumor growth in xenograft studies in vivo.